Compare Snowflake Inc (SNOW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Snowflake Inc trades at $368.89 (market cap $121.15B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Snowflake Inc is far larger — about 12× State Street SPDR S&P Biotech ETF's market cap, and Snowflake Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Snowflake Inc for 54 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SNOW | XBI | |
|---|---|---|
Market Cap | $121.15B | $10.11B |
Volume | 3,986,549 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $368.89 | $169.55 |
52-Week Low | $121.11 | $104.99 |
Typical Hold Time | 54 Days | 38 Days |
Enterprise Value | $121.57B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $343.40, up 3.17% with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $3.63 billion in 2025 but remains unprofitable with a net income margin of -20.07%. Recent positive developments include strategic partnerships with UiPath and a $3.75 billion convertible note offering to fund growth initiatives.
Snowflake presents a growth investment opportunity with strong analyst support (81% buy ratings) and a $418 price target, but faces execution risks from persistent losses and high valuation multiples. The stock's upside depends on continued revenue expansion and path to profitability amid competitive cloud data market pressures.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
